Report : Middle East & Africa Parenteral Nutrition Market Forecast to 2030 - Regional Analysis - by Nutrient Type (Single Dose Amino Acid Solution, Parenteral Lipid Emulsion, Carbohydrates, Trace Elements, and Vitamins and Minerals) and End User (Hospitals, Clinics, and Others)
At 4.1% CAGR, Middle East & Africa Parenteral Nutrition Market is Projected to be Worth US$ 288.90 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Middle East & Africa parenteral nutrition market was valued at US$ 208.88 million in 2022 and is expected to reach US$ 288.90 million by 2030, registering a CAGR of 4.1% from 2022 to 2030. Rise in prevalence of gastrointestinal diseases and innovation in formulations of nutrition products are among the critical factors attributed to the Middle East & Africa parenteral nutrition market expansion.
Crohn's disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and gastric cancer are a few examples of gastrointestinal diseases. According to the "Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study," published in January 2021, functional gastrointestinal disorders have affected over 40% of people across the globe.
Based on the Global Burden of Disease Study 2019, ~4.9 million cases of inflammatory bowel disease (IBD) were recorded worldwide in 2019. Ulcerative colitis and Crohn's disease are two of the commonly diagnosed IBDs. Crohn's disease is a complex, chronic disorder primarily affecting the digestive system. According to the IBS Global Impact Report, in 2016, the Middle East and African populations had a prevalence rate of irritable bowel syndrome of 5.8%. Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of the colon, abnormal composition of serotonin in the colon, and mild celiac disease are among the risk factors that cause irritable bowel syndrome. Further, chronic inflammation and reduced immunosurveillance caused by IBD may contribute to the development of gastric cancer.
Patients with gastrointestinal diseases are at an elevated risk of nutritional deterioration as they are asked to fast before undergoing diagnostic tests. They might also face nutritional deterioration due to therapeutic dietary restriction and loss of appetite caused by anorexia or altered nutritional requirements, which can be a result of the disease itself. Hence, medical nutrition is recommended for gastrointestinal disease patients as they are unable to ingest food. Further, the parenteral routes are preferred to provide them with essential nutrients. Some people might not show compatibility with tube insertion, which makes meeting their calorie and nutrient needs difficult. In such cases, parenteral nutrition is preferred to ensure their bodies remain hydrated and meet the calorie and other nutrient intake required to maintain physical well-being and function. Parenteral nutrition is indicated when patients cannot meet their nutritional needs as they are diagnosed with diseases such as cancer and chronic diseases, which affect the gastrointestinal tract. This type of nutrition is highly preferred as a therapy option for most patients suffering from severe SBS. Therefore, the growing prevalence of gastrointestinal diseases drives the parenteral nutrition market.
On the contrary, mechanical, gastrointestinal, and metabolic complications associated with parenteral feeding systems hampers the growth of Middle East & Africa parenteral nutrition market.
Based on nutrient type, the Middle East & Africa parenteral nutrition market is categorized into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins and minerals. The single dose amino acid solution segment held 33.1% market share in 2022, amassing US$ 69.21 million. It is projected to garner US$ 95.16 million by 2030 to register 4.1% CAGR during 2022-2030.
In terms of end user, the Middle East & Africa parenteral nutrition market is segmented into hospitals, clinics, and others. The hospitals segment held 59.3% share of Middle East & Africa parenteral nutrition market in 2022, amassing US$ 123.95 million. It is projected to garner US$ 168.62 million by 2030 to expand at 3.9% CAGR during 2022-2030.
Based on country, the Middle East & Africa parenteral nutrition market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 35.5% share of Middle East & Africa parenteral nutrition market in 2022. It was assessed at US$ 73.92 million in 2022 and is likely to hit US$ 108.83 million by 2030, exhibiting a CAGR of 5.0% during 2022-2030.
Key players operating in the Middle East & Africa parenteral nutrition market are ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Aculife Healthcare Pvt Ltd, and Vifor Pharma Management AG, among others.
- In March 2020, Fresenius Kabi AG announced the receiving of FDA approval for its SMOFlipid lipid injectable emulsion. The injection is intended for pediatric patients, including term and preterm neonates in the United States. The product is the first and only four-oil lipid emulsion for parenteral nutrition patients of every age. The SMOFlipid can be used in all facility centers.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com